PMID- 20686456
OWN - NLM
STAT- MEDLINE
DCOM- 20110216
LR  - 20220318
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 35
IP  - 12
DP  - 2010 Nov
TI  - Relapse prevention in schizophrenia and schizoaffective disorder with risperidone 
      long-acting injectable vs quetiapine: results of a long-term, open-label, 
      randomized clinical trial.
PG  - 2367-77
LID - 10.1038/npp.2010.111 [doi]
AB  - Chronic management of schizophrenia and schizoaffective disorders is frequently 
      complicated by symptomatic relapse. An open-label, randomized, active-controlled, 
      2-year trial evaluated 710 patients with schizophrenia or related disorders who 
      were switched from stable treatment with oral risperidone, olanzapine, or 
      conventional neuroleptics to risperidone long-acting injectable (RLAI) or oral 
      quetiapine. Primary effectiveness evaluation was time-to-relapse. Safety 
      evaluations included adverse events (AEs) reported for the duration of the study, 
      Extrapyramidal Symptom Rating Scale (ESRS), clinical laboratory tests, and vital 
      signs. A total of 666 patients (n=329 RLAI, n=337 quetiapine) were evaluable for 
      effectiveness measures. Baseline demographics were similar between treatment 
      groups. Kaplan-Meier estimate of time-to-relapse was significantly longer with 
      RLAI (p<0.0001). Relapse occurred in 16.5% of patients with RLAI and 31.3% with 
      quetiapine. RLAI and quetiapine were both safe and well tolerated. Weight gain 
      affected 7% of patients with RLAI and 6% with quetiapine, with mean end point 
      increases of 1.25+/-6.61 and 0+/-6.55 kg, respectively. There were no significant 
      between-group differences in weight gain. ESRS total scores decreased similarly 
      after randomization to either RLAI or quetiapine. Extrapyramidal AEs occurred in 
      10% of patients with RLAI and 6% with quetiapine. Treatment-emergent potentially 
      prolactin-related AEs were reported in 15 (5%) patients with RLAI and 5 (2%) 
      patients with quetiapine; hyperprolactinemia was reported in 43 (13.1%) patients 
      with RLAI and 5 (1.5%) patients with quetiapine. Somnolence occurred in 2% of 
      patients with RLAI and 11% with quetiapine. To our knowledge, this is the first 
      report of a randomized clinical trial directly comparing relapse prevention with 
      a second-generation long-acting injectable antipsychotic and oral therapy. 
      Time-to-relapse in stable patients with schizophrenia or schizoaffective disorder 
      was significantly longer in patients randomized to RLAI compared with those 
      randomized to oral quetiapine. Both antipsychotics were generally well tolerated.
FAU - Gaebel, Wolfgang
AU  - Gaebel W
AD  - Department of Psychiatry and Psychotherapy, Heinrich-Heine University, 
      Dusseldorf, Germany. wolfgang.gaebel@lvr.de
FAU - Schreiner, Andreas
AU  - Schreiner A
FAU - Bergmans, Paul
AU  - Bergmans P
FAU - de Arce, Rosario
AU  - de Arce R
FAU - Rouillon, Frederic
AU  - Rouillon F
FAU - Cordes, Joachim
AU  - Cordes J
FAU - Eriksson, Lars
AU  - Eriksson L
FAU - Smeraldi, Enrico
AU  - Smeraldi E
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100804
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Dibenzothiazepines)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
EIN - Neuropsychopharmacology. 2011 Jan;36(2):548
MH  - Administration, Oral
MH  - Adult
MH  - Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Delayed-Action Preparations
MH  - Dibenzothiazepines/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular
MH  - Male
MH  - Psychotic Disorders/*drug therapy/*prevention & control
MH  - Quetiapine Fumarate
MH  - Risperidone/administration & dosage/adverse effects/*therapeutic use
MH  - Schizophrenia/*drug therapy/*prevention & control
MH  - Secondary Prevention
PMC - PMC3055334
EDAT- 2010/08/06 06:00
MHDA- 2011/02/17 06:00
PMCR- 2011/11/01
CRDT- 2010/08/06 06:00
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2011/02/17 06:00 [medline]
PHST- 2011/11/01 00:00 [pmc-release]
AID - npp2010111 [pii]
AID - 10.1038/npp.2010.111 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2010 Nov;35(12):2367-77. doi: 10.1038/npp.2010.111. Epub 
      2010 Aug 4.